Beigene Ltd
6160.HK- Latest Trade
- trading higher98.85HKD
- 1.9
- 1.96%
- As of May 14, 2024. Values delayed up to 15 minutes
- Today's Range
- 97.45 - 99.90
- 52 Week Range
- 75.45 - 148.00
- Previous Close
- 96.95
- Open
- 97.95
- Volume
- 941,117.00
- 3 Month Average Trading Volume
- 27.63
- Shares Out (Mil)
- 1,359.00
- Market Cap
- 136,947.80
- Forward P/E
- -20.02
- Dividend Yield
- 0.00
Key Statistics
1.75 mean rating - 16 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 6.34
- Price To Book (Quarterly)
- 0.00
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- 0.00
- Return On Equity (TTM)
- 0.00
2024 (millions HKD)
About Beigene Ltd (6160.HK)
Company Information
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Address
94 Solaris Avenue,, Camana BayGRAND CAYMAN, BEJ
KY1-1108
Cayman Islands
Industry
Biotechnology & Drugs
Executive Leadership
- John Victor Oyler
- Co-Founder, Executive Chairman of the Board, Chief Executive Officer
- Xiaobin Wu
- President, Chief Operating Officer, General Manager - China
- Xiaodong Wang
- Co-Founder, Non-Executive Director
- Julia Wang
- Chief Financial Officer
- Lai Wang
- Global Head of R&D
- Ranjeev Krishana
- Lead Non-Executive Independent Director
- Olivier Brandicourt
- Independent Non-Executive Director
- Han Dugan
- Non-Executive Independent Director
- Donald Wayne Glazer
- Non-Executive Independent Director
- Michael J. Goller
- Non-Executive Independent Director
- Anthony C. Hooper
- Non-Executive Independent Director
- Alessandro Riva
- Non-Executive Independent Director
- Corazon Dating Sanders
- Non-Executive Independent Director
- Qingqing Yi
- Non-Executive Independent Director
Financials
Source: LSEG - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 2,358.00 | 0.94% |
| Copper | 884.35 | 0.10% |
| Brent Crude Oil | 82.40 | 1.15% |
| CBOT Soybeans | 1,204.75 | 0.06% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 5,237.85 | 0.31% |
| Euro STOXX 50 | 5,080.29 | 0.03% |
| FTSE 100 | 8,428.13 | 0.16% |
| Nikkei 225 | 38,356.06 | 0.46% |
Source: LSEG - data delayed by at least 15 minutes
Latest News
- BusinessBeiGene to buy global rights to Ensem's experimental cancer therapy
BeiGene said on Tuesday it would buy the global license for a cancer therapy that is ready to enter early-stage trial from U.S.-based biotech company Ensem Therapeutics.
- BusinessBeiGene to go solo with cancer drug after Novartis deal termination
BeiGene and Swiss drugmaker Novartis have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such discontinuation in just over two months.
